The medical benefits of approaching these diseases proactively, as opposed to reactively, are substantial. Customers will be able to catch warning signs early, meaning treatment is likely to be less invasive, with a higher success rate. Unfortunately North America, like many regions, has yet to make substantial investments in preventative healthcare. This just makes companies like Prenuvo, and the VCs who fund them, increasingly necessary.

This funding, however has been substantial, and having closed a Series A funding round in 2022 Prenuvo has moved swiftly to open new clinics across the United States. Its next step is to improve the accessibility of its service - currently scans cost about $1000, but improvements in the technology and working processes will cut the cost by two thirds or more and greatly expand Prenuvo's addressable market.